Recent Developments in Microbiome Therapeutics Recent-Developments-in-Microbiome-Therapeutics-Nov | Page 17

Company
Location
Funding to
date Disease Indications
Lead
Candidate
Axial
Biotherapeutics USA $19,500,000 CNS Disorders –
LNC
Therapeutics France $11,610,000 Obesity and associated cardiometabolic
diseases Temys
TargEDys France $10,264,560 Obesity ProbioSatys™
Underweight ProbioNutrys™
Naked Biome USA $9,400,000 Skin diseases –
Azitra Inc. USA $3,250,000 Skin diseases AZT-01
MicroBiome
Therapeutics USA $3,043,445 Prediabetes, Diabetes type 2 NM504
$199,000 Skin diseases –
C. difficile Infection CP101
Ulcerative colitis FIN-524
Mental Health –
Xycrobe
USA
Therapeutics Inc.
Finch
Therapeutics
Group USA HoloBiome USA Unknown Mental Health –
Commense
Health USA Unknown Asthma, Allergy and other Pediatric
Autoimmune Disorders COM101
NUBiyota Unknown Unknown C. difficile Infection MET-2
17
Unknown
Stage of Development
Discovery
Preclinical
Clinical
Phase 1
Phase 2
Phase 3
Recent Developments in Microbiome Therapeutics